These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 17875725)

  • 21. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.
    Mao Y; Desai SD; Ting CY; Hwang J; Liu LF
    J Biol Chem; 2001 Nov; 276(44):40652-8. PubMed ID: 11546768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
    Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
    J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
    Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
    Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
    Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
    J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
    Kik K; Szmigiero L
    Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
    Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
    Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
    Herman EH; Zhang J; Chadwick DP; Ferrans VJ
    Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
    Wu X; Hasinoff BB
    Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
    Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
    Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexrazoxane (ICRF-187).
    Weiss G; Loyevsky M; Gordeuk VR
    Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase 2β Induces DNA Breaks To Regulate Human Papillomavirus Replication.
    Kaminski P; Hong S; Kono T; Hoover P; Laimins L
    mBio; 2021 Feb; 12(1):. PubMed ID: 33563836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
    Jirkovská A; Karabanovich G; Kubeš J; Skalická V; Melnikova I; Korábečný J; Kučera T; Jirkovský E; Nováková L; Bavlovič Piskáčková H; Škoda J; Štěrba M; Austin CA; Šimůnek T; Roh J
    J Med Chem; 2021 Apr; 64(7):3997-4019. PubMed ID: 33750129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
    Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
    Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
    Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
    Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
    Hasinoff BB; Abram ME; Barnabé N; Khélifa T; Allan WP; Yalowich JC
    Mol Pharmacol; 2001 Mar; 59(3):453-61. PubMed ID: 11179439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.